| Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) (NCT06136624) | Merck Sharp & Dohme LLC | 2023-12-31 |
| A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) (NCT06079879) | Merck Sharp & Dohme LLC | 2023-12-31 |
| Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupus Erythematosus (MK-6194-006) (NCT06161116) | Merck Sharp & Dohme LLC | 2023-12-27 |
| A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) (NCT06099782) | Merck Sharp & Dohme LLC | 2023-12-26 |
| A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) (NCT06136650) | Merck Sharp & Dohme LLC | 2023-12-18 |
| Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) (NCT06170788) | Merck Sharp & Dohme LLC | 2023-12-15 |
| A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) (NCT06136559) | Merck Sharp & Dohme LLC | 2023-12-13 |
| Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) (NCT06132958) | Merck Sharp & Dohme LLC | 2023-12-06 |
| A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) (NCT06077760) | Merck Sharp & Dohme LLC | 2023-12-06 |
| A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007) (NCT06113328) | Merck Sharp & Dohme LLC | 2023-11-27 |
| A Clinical Study of MK-7962 in Healthy Chinese Participants (MK-7962-021) (NCT06843460) | Merck Sharp & Dohme LLC | 2023-11-22 |
| A Study of MK-2225 in Healthy Participants (MK-2225-003) (NCT06643390) | Merck Sharp & Dohme LLC | 2023-11-21 |
| A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014) (NCT06052566) | Merck Sharp & Dohme LLC | 2023-11-21 |
| A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005) (NCT06104449) | Merck Sharp & Dohme LLC | 2023-11-14 |
| Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) (NCT06074588) | Merck Sharp & Dohme LLC | 2023-11-12 |
| A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Atorvastatin in Healthy Adult Participants (MK-0616-024) (NCT06699355) | Merck Sharp & Dohme LLC | 2023-11-08 |
| Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007) (NCT06045507) | Merck Sharp & Dohme LLC | 2023-11-08 |
| A Study of the Effect of Nemtabrutinib (MK-1026) on the Plasma Levels of Digoxin in Healthy Participants (MK-1026-012) (NCT06625827) | Merck Sharp & Dohme LLC | 2023-11-07 |
| A Study of the Effects of Itraconazole on the Plasma Levels of Nemtabrutinib (MK-1026-013) (NCT06688045) | Merck Sharp & Dohme LLC | 2023-10-30 |
| Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008) (NCT06049212) | Merck Sharp & Dohme LLC | 2023-10-26 |
| A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001) (NCT06052059) | Merck Sharp & Dohme LLC | 2023-10-25 |
| A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39) (NCT06041802) | Merck Sharp & Dohme LLC | 2023-10-20 |
| A Drug-Drug Interaction Study of Diltiazem and MK-1167 in Healthy Adult Participants (MK-1167-006) (NCT06703463) | Merck Sharp & Dohme LLC | 2023-10-17 |
| Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes (NCT06008756) | Merck Sharp & Dohme LLC | 2023-10-09 |
| A Study to Evaluate the Effect of Food on Nemtabrutinib (MK-1026) in Healthy Participants (MK-1026-017) (NCT06772818) | Merck Sharp & Dohme LLC | 2023-10-02 |
| Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) (NCT06036836) | Merck Sharp & Dohme LLC | 2023-09-29 |
| A Study to Evaluate Laser Speckle Contrast Imaging to Assess Changes in Chemical Agent-Induced Skin Blood Flow in Healthy Participants (MK-0000-420) (NCT06809569) | Merck Sharp & Dohme LLC | 2023-09-25 |
| A Clinical Study of MK-6552 and Modafinil in Healthy Men (MK-6552-005) (NCT06665230) | Merck Sharp & Dohme LLC | 2023-09-20 |
| A Study to Evaluate the Effect of Food, Formulation, and a Proton Pump Inhibitor (PPI) on Calderasib (MK-1084) in Healthy Adult Participants (MK-1084-003) (NCT06619314) | Merck Sharp & Dohme LLC | 2023-09-20 |
| A Study of MK-1167 in Healthy Elderly Participants (MK-1167-004) (NCT06625840) | Merck Sharp & Dohme LLC | 2023-09-18 |
| A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001) (NCT05953740) | Merck Sharp & Dohme LLC | 2023-09-15 |
| A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007) (NCT06586671) | Merck Sharp & Dohme LLC | 2023-08-28 |
| Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated With Experimental Influenza Virus (MK-4482-019) (NCT05818124) | Merck Sharp & Dohme LLC | 2023-08-21 |
| A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE) (NCT06783192) | Merck Sharp & Dohme LLC | 2023-08-14 |
| A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids (NCT05952856) | Merck Sharp & Dohme LLC | 2023-08-10 |
| A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH) (NCT05952869) | Merck Sharp & Dohme LLC | 2023-08-08 |
| A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). (NCT05947851) | Merck Sharp & Dohme LLC | 2023-08-08 |
| A Study of the Effect of Efavirenz on the Plasma Levels of Nemtabrutinib (MK-1026-014) (NCT06698016) | Merck Sharp & Dohme LLC | 2023-07-25 |
| A Study to Evaluate the Effect of Food on Nemtabrutinib (MK-1026) in Healthy Participants (MK-1026-016) (NCT06772805) | Merck Sharp & Dohme LLC | 2023-07-24 |
| Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020) (NCT05934292) | Merck Sharp & Dohme LLC | 2023-07-20 |
| A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001) (NCT05933577) | Merck Sharp & Dohme LLC | 2023-07-19 |
| Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) (NCT05853367) | Merck Sharp & Dohme LLC | 2023-07-06 |
| A Clinical Study of MK-4482 in Chinese Healthy Male Participants (MK-4482-009) (NCT06816030) | Merck Sharp & Dohme LLC | 2023-06-28 |
| A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013) (NCT05877547) | Merck Sharp & Dohme LLC | 2023-06-23 |
| Single Dose Study of MK-2060 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Older Japanese Participants on Dialysis (MK-2060-012) (NCT05769595) | Merck Sharp & Dohme LLC | 2023-06-14 |
| A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension (NCT06212752) | Merck Sharp & Dohme LLC | 2023-06-13 |
| Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036) (NCT05714085) | Merck Sharp & Dohme LLC | 2023-05-31 |
| A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) (NCT05319730) | Merck Sharp & Dohme LLC | 2023-05-16 |
| A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020) (NCT05818137) | Merck Sharp & Dohme LLC | 2023-05-10 |
| MK-8510 Monotherapy for the Treatment of Anti-retroviral naïve Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8510-002) (NCT05700734) | Merck Sharp & Dohme LLC | 2023-04-17 |
| A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045) (NCT05763823) | Merck Sharp & Dohme LLC | 2023-03-24 |
| MK-6194 Site of Injection Study in Healthy Adult Participants (MK-6194-013) (NCT06649877) | Merck Sharp & Dohme LLC | 2023-03-20 |
| A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054) (NCT05766501) | Merck Sharp & Dohme LLC | 2023-03-17 |
| A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) (NCT05624554) | Merck Sharp & Dohme LLC | 2023-03-16 |
| Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD (NCT05612035) | Merck Sharp & Dohme LLC | 2023-03-16 |
| A Study to Evaluate the Metabolism, Excretion, and Mass Balance of [¹⁴C]Enlicitide Chloride ([¹⁴C]MK-0616) in Healthy Participants (MK-0616-016) (NCT06658626) | Merck Sharp & Dohme LLC | 2023-03-10 |
| DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053) (NCT05705349) | Merck Sharp & Dohme LLC | 2023-03-08 |
| A Single- and Multiple-Dose Study of Enlicitide Chloride (MK-0616) in Healthy Chinese Adult Participants (MK 0616-010) (NCT06814106) | Merck Sharp & Dohme LLC | 2023-03-06 |
| Single-Ascending Dose Study of MK-2060 in Healthy Chinese Male Adult Participants (MK-2060-009) (NCT06843993) | Merck Sharp & Dohme LLC | 2023-03-01 |
| A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051) (NCT05631093) | Merck Sharp & Dohme LLC | 2023-02-20 |
| A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052) (NCT05630755) | Merck Sharp & Dohme LLC | 2023-02-17 |
| Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008) (NCT05696080) | Merck Sharp & Dohme LLC | 2023-02-13 |
| A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002) (NCT05673460) | Merck Sharp & Dohme LLC | 2023-02-13 |
| A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011) (NCT05656040) | Merck Sharp & Dohme LLC | 2023-02-08 |
| Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) (NCT05609968) | Merck Sharp & Dohme LLC | 2023-02-06 |
| A Study to Evaluate Molnupiravir Tablet Formulation Compared to the Molnupiravir Capsule Formulation in Healthy Adult Participants (MK-4482-011) (NCT06615869) | Merck Sharp & Dohme LLC | 2023-01-20 |
| Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008) (NCT05587712) | Merck Sharp & Dohme LLC | 2023-01-19 |
| A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001) (NCT05594043) | Merck Sharp & Dohme LLC | 2022-12-21 |
| Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008) (NCT05602727) | Merck Sharp & Dohme LLC | 2022-12-02 |
| MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004) (NCT05494736) | Merck Sharp & Dohme LLC | 2022-11-17 |
| A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A) (NCT05562830) | Merck Sharp & Dohme LLC | 2022-11-16 |
| Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017) (NCT05559905) | Merck Sharp & Dohme LLC | 2022-11-02 |
| A Study of MK-0616 in Healthy Adult Participants (MK-0616-009) (NCT06592339) | Merck Sharp & Dohme LLC | 2022-10-25 |
| A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008) (NCT05508867) | Merck Sharp & Dohme LLC | 2022-10-18 |
| A Study of Islatravir (MK-8591) in Trans and Gender Diverse Participants (MK-8591-035) (NCT05130086) | Merck Sharp & Dohme LLC | 2022-10-17 |
| A Study of Enlicitide Chloride (MK-0616) in Healthy Participants and Participants Taking Statins (MK-0616-012) (NCT06655311) | Merck Sharp & Dohme LLC | 2022-09-30 |
| Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) (NCT05514444) | Merck Sharp & Dohme LLC | 2022-09-25 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5) (NCT05526716) | Merck Sharp & Dohme LLC | 2022-09-23 |
| A Clinical Study of Efinopegdutide (MK-6024) in Healthy Chinese Volunteers (MK-6024-011) (NCT06836037) | Merck Sharp & Dohme LLC | 2022-09-05 |
| A Clinical Study To Understand How Radiolabeled MK-5475 Is Taken Up By The Body, Broken Down And Then Removed From The Body in Healthy Participants (MK-5475-011) (NCT06777602) | Merck Sharp & Dohme LLC | 2022-08-15 |
| A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4) (NCT05464420) | Merck Sharp & Dohme LLC | 2022-08-12 |
| A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024) (NCT05468697) | Merck Sharp & Dohme LLC | 2022-08-10 |
| Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008) (NCT05450198) | Merck Sharp & Dohme LLC | 2022-08-08 |
| A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A) (NCT05342636) | Merck Sharp & Dohme LLC | 2022-07-27 |
| A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study (NCT05899049) | Merck Sharp & Dohme LLC | 2022-07-27 |
| Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002) (NCT05446870) | Merck Sharp & Dohme LLC | 2022-07-25 |
| V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071) (NCT05450705) | Merck Sharp & Dohme LLC | 2022-07-22 |
| A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) (NCT05458297) | Merck Sharp & Dohme LLC | 2022-07-21 |
| A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007) (NCT05406401) | Merck Sharp & Dohme LLC | 2022-07-14 |
| Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7) (NCT05393037) | Merck Sharp & Dohme LLC | 2022-07-13 |
| A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021) (NCT04994522) | Merck Sharp & Dohme LLC | 2022-07-12 |
| A Study of Elpipodect (MK-8189) in Participants With Schizophrenia (MK-8189-014) (NCT05406440) | Merck Sharp & Dohme LLC | 2022-07-12 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6) (NCT05420961) | Merck Sharp & Dohme LLC | 2022-07-12 |
| Elpipodect (MK-8189) Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017) (NCT05227118) | Merck Sharp & Dohme LLC | 2022-07-01 |
| A Study to Evaluate Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment (MK-4482-003) (NCT05386758) | Merck Sharp & Dohme LLC | 2022-06-29 |
| A Study of Belzutifan (MK-6482) in Participants With Hepatic Impairment (MK-6482-020) (NCT04995484) | Merck Sharp & Dohme LLC | 2022-06-24 |
| A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001) (NCT05382325) | Merck Sharp & Dohme LLC | 2022-06-16 |
| A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016) (NCT05386589) | Merck Sharp & Dohme LLC | 2022-06-14 |
| A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study (NCT05600309) | Merck Sharp & Dohme LLC | 2022-06-14 |
| MK-2060 and Clopidogrel Co-administration Safety and Tolerability Study in Participants With End-Stage Renal Disease (ESRD) (MK-2060-008) (NCT05335005) | Merck Sharp & Dohme LLC | 2022-05-30 |